Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, investigator-masked, parallel group, and
active-comparator controlled study investigating the clinical outcomes for visual acuity and
macular thickness after treatment with Bromday (bromfenac ophthalmic solution) 0.09% QD or
Nevanac (nepafenac ophthalmic suspension) 0.1% TID in subjects who have undergone cataract
extraction with posterior chamber intraocular lens implantation.